ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the first successful dosing in a Phase III clinical trial for IMM01 (Timdarpacept) in combination with tislelizumab, aimed at treating relapsed or refractory classical Hodgkin lymphoma. The company’s core product, IMM01, is a novel molecule that activates macrophages and has a favorable safety profile, with global intellectual property rights secured across major markets. While the development holds promise, the company cautions shareholders and potential investors that the successful commercialization of IMM01 is not guaranteed.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
